Issue

Vol. 63 No. 12: Issue 12

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

In vitro effects of novel type M-V-O derivatives on Xanthine Oxidase

https://doi.org/10.14715/10.14715/cmb/2017.63.12.7
Mustafa Oğuzhan Kaya
Faculty of Veterinary Medicine, Division of Basic Sciences, Biochemistry Department, Siirt University, Siirt, Turkey
Gülşah í‡eli̇k Gül
Faculty of Arts and Sciences, Department of Chemistry/Inorganic Chemistry Section, BalikesirUniversity, Balikesir Turkey
Figen Kurtuluş
Faculty of Arts and Sciences, Department of Chemistry/Inorganic Chemistry Section, BalikesirUniversity, Balikesir Turkey

Corresponding Author(s) : Mustafa Oğuzhan Kaya

m.oguzhankaya@gmail.com

Cellular and Molecular Biology, Vol. 63 No. 12: Issue 12

Abstract

Xanthine Oxidase (XO) is related with different diseases such as vascular, gout, nephropathy and renal stone diseases that are relevant to high uric acid levels and oxidative stress. Some common natural inhibitors of xanthine oxidase are known as rosmarinic acid and apigenin. With this study, we aimed to determine inhibitory effects of originally synthesized new generation transition metal vanadates on Xanthine Oxidase (XO) from bovine milk. Because, Xanthine oxidase inhibitors are typically used in the treatment of gout and nephropathy and renal stone diseases linked to hyperuricaemia. We found considerable IC50 constants for inhibition of XO. Among the synthesized compounds, Cu"’V"’O was found to be the most active (IC50 = 7.119 mM) for inhibition of XO.

Keywords

Xanthine Oxidase Vanadium Transition metal Inhibition IC50.
Kaya, M. O., Gül, G. í‡eli̇k, & Kurtuluş, F. (2017). In vitro effects of novel type M-V-O derivatives on Xanthine Oxidase. Cellular and Molecular Biology, 63(12), 25–28. https://doi.org/10.14715/10.14715/cmb/2017.63.12.7
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. REFERENCES
  2. Jungwirth, U.; Kowol, C. R.; Keppler, B. K.; Christian, G. Anticancer Activity of Metal Complexes : Involvement of Redox Processes. Antioxidants & redox signaling 2012; 15: 1085–1127.
  3. Yin, G. Active transition metal oxo and hydroxo moieties in nature's redox, enzymes and their synthetic models: Structure and reactivity relationships. Coordination Chemistry Reviews 2010; 254: 1826–1842.
  4. Monney, A.; Albrecht, M. Transition metal bioconjugates with an organometallic link between the metal and the biomolecular scaffold. Coordination Chemistry Reviews 2013; 257: 2420–2433.
  5. Front Matter. In Biomimetic Oxidations Catalyzed by Transition Metal Complexes; Published By Imperial College Press And Distributed By World Scientific Publishing Co., 2000; 1-18.
  6. Foote, C. S. Active oxygen in chemistry. 1995; 2: 280–333.
  7. Arner, E. S. J.; Holmgren, A. The thioredoxin system in cancer. Seminars in cancer biology 2006; 16: 420–426.
  8. Arredondo, M.; Nunez, M. Iron and copper metabolism; 2005; 26.
  9. Go, Y.-M.; Jones, D. P. Redox compartmentalization in eukaryotic cells. Biochimica et biophysica acta 2008; 1780: 1273–1290.
  10. Hentze, M. W.; Muckenthaler, M. U.; Andrews, N. C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117: 285–297.
  11. Li, Y.-G.; Shi, D.-H.; Zhu, H.-L.; Yan, H.; Ng, S. W. Transition metal complexes (M = Cu, Ni and Mn) of Schiff-base ligands: Syntheses, crystal structures, and inhibitory bioactivities against urease and xanthine oxidase. Inorganica Chimica Acta 2007; 360: 2881–2889.
  12. Hearse, D. J.; Manning, A. S.; Downey, J. M.; Yellon, D. M. Xanthine oxidase: a critical mediator of myocardial injury during ischemia and reperfusion? Acta physiologica Scandinavica. Supplementum 1986; 548: 65–78.
  13. You, Z. L.; Shi, D. H.; Zhu, H. L. The inhibition of xanthine oxidase by the Schiff base zinc(II) complex. Inorganic Chemistry Communications 2006; 9: 642–644.
  14. Frederiks, W. M.; Marx, F. A histochemical procedure for light microscopic demonstration of xanthine oxidase activity in unfixed cryostat sections using cerium ions and a semipermeable membrane technique. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1993; 41: 667–670.
  15. Björck, L.; Claesson, O. Xanthine oxidase as a source of hydrogen peroxide for the lactoperoxidase system in milk. Journal of Dairy Science 1979; 62: 1211–1215.
  16. Tubaro, E.; Lotti, B.; Cavallo, G.; Croce, C.; Borelli, G. Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism. Biochemical pharmacology 1980; 29: 1939–1943.
  17. Jarasch, E. D.; Grund, C.; Bruder, G.; Heid, H. W.; Keenan, T. W.; Franke, W. W. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981; 25: 67–82.
  18. Peden, D. B.; Hohman, R.; Brown, M. E.; Mason, R. T.; Berkebile, C.; Fales, H. M.; Kaliner, M. A. Uric acid is a major antioxidant in human nasal airway secretions. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 7638–7642.
  19. Kooij, A.; Bosch, K. S.; Frederiks, W. M.; Van Noorden, C. J. F. High levels of xanthine oxidoreductase in rat endothelial, epithelial and connective tissue cells. Virchows Archiv B Cell Pathology Zell-pathologie 1992; 62: 143–150.
  20. Becker, B. F. Towards the physiological function of uric acid. Free radical biology & medicine 1993; 14: 615–631.
  21. Kooij, A. A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase. The Histochemical journal 1994; 26: 889–915.
  22. Van den Munckhof, R. J.; Denyn, M.; Tigchelaar-Gutter, W.; Schipper, R. G.; Verhofstad, A. A.; Van Noorden, C. J.; Frederiks, W. M. In situ substrate specificity and ultrastructural localization of polyamine oxidase activity in unfixed rat tissues. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1995; 43: 1155–1162.
  23. Frederiks, W. M.; Vreeling-Sindelarova, H. Ultrastructural localization of xanthine oxidoreductase activity in isolated rat liver cells. Acta histochemica 2002; 104: 29–37.
  24. Ozer, N.; Muftuoglu, M.; Ataman, D.; Ercan, A.; Ogus, I. H. Simple, high-yield purification of xanthine oxidase from bovine milk. Journal of biochemical and biophysical methods 1999; 39: 153–159.
  25. Beyaztas¸ S., A. O. Affinity Effects of Some Antibiotics on xanthine oxidase enzyme activities in vitro. Hacettepe J. Biol. & Chem. 2011; 39: 195–205.
  26. McManaman, J. L.; Shellman, V.; Wright, R. M.; Repine, J. E. Purification of rat liver xanthine oxidase and xanthine dehydrogenase by affinity chromatography on benzamidine-sepharose. Archives of biochemistry and biophysics 1996; 332: 135–141.
  27. Massey, V.; Brumby, P. E.; Komai, H. Studies on milk xanthine oxidase. Some spectral and kinetic properties. The Journal of biological chemistry 1969; 244: 1682–1691.
  28. Hille, R. Structure and Function of Xanthine Oxidoreductase. European Journal of Inorganic Chemistry 2006; 2006: 1913–1926.
  29. Berg, J.; Tymoczko, J.; Stryer, L. Biochemistry. Biochemistry 2007; 117–144.
  30. Cao, H.; E Hall, J.; Hille, R. Substrate Orientation and Specificity in Xanthine Oxidase: Crystal Structures of the Enzyme in Complex with Indole-3-Acetaldehyde and Guanine.; 2014;53 (3): 533–541.
  31. Parks, D. A.; Granger, D. N. Xanthine oxidase: biochemistry, distribution and physiology. Acta physiologica Scandinavica. Supplementum 1986; 548: 87–99.
  32. Bray, R. C. 6 Molybdenum Iron-Sulfur Flauin Hydroxylases and Related Enzymes; 1975;12: 299-419.
  33. Topham, R. W.; Walker, M. C.; Calisch, M. P. Liver xanthine dehydrogenase and iron mobilization. Biochemical and Biophysical Research Communications 1982; 109: 1240–1246.
  34. Godber, B. L. J.; Doel, J. J.; Sapkota, G. P.; Blake, D. R.; Stevens, C. R.; Eisenthal, R.; Harrison, R. Reduction of Nitrite to Nitric Oxide Catalyzed by Xanthine Oxidoreductase. Journal of Biological Chemistry 2000; 275: 7757–7763.
  35. Brunelli, L.; Crow, J. P.; Beckman, J. S. The comparative toxicity of nitric oxide and peroxynitrite to Escherichia coli. Archives of biochemistry and biophysics 1995; 316: 327–334.
  36. Nagao, A.; Seki, M.; Kobayashi, H. Inhibition of xanthine oxidase by flavonoids. Bioscience, biotechnology, and biochemistry 1999; 63: 1787–1790.
  37. Ahmad, I.; Ijaz, F.; Fatima, I.; Ahmad, N.; Chen, S.; Afza, N.; Malik, A. Xanthine oxidase/tyrosinase inhibiting, antioxidant, and antifungal oxindole alkaloids from Isatis costata. Pharmaceutical biology 2010; 48: 716–721.
  38. Sharma, S.; Sharma, K.; Ojha, R.; Kumar, D.; Singh, G.; Nepali, K.; Bedi, P. M. S. Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors. Bioorganic & medicinal chemistry letters 2014; 24: 495–500.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 924 Download : 338